HealthBeacon SHA

Director's Dealing • Nov 1, 2022

National Storage Mechanism | Additional information

RNS Number : 7958E

HealthBeacon PLC

01 November 2022

01 November 2022

HealthBeacon plc

Director/PDMR Shareholding

Dublin, Ireland - 1 November 2022: HealthBeacon plc (HBCN.ID) ("HealthBeacon" or "the Company"), a digital therapeutics company that develops products for managing injectable medications for patients in the home, today announces that Jim Joyce, Chief Executive Officer and Co-Founder, has purchased 9,439 ordinary shares at a price of €2.10. Following this purchase Jim Joyce holds 1,811,786 shares representing 10.73% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of ordinary shares purchased.

Notification - of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them

This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Jim Joyce

2

Reason for the notification

a)

Position/status

Person discharging managerial responsibility - Chief Executive Officer

b)

Initial Notification Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

HealthBeacon plc

b)

LEI

635400DZJITFJMT8T166

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial  instrument, type  of instrument

Identification code

Ordinary shares of €0.0025 each ("HealthBeacon Shares")

IE00014QAJZ5

b)

Nature of the transaction  

Purchase of HealthBeacon Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
€2.10 per ordinary share	9,439

d)

Aggregated information

- Aggregated volume

- Price

n/a single transaction

e)

Date of the transaction

28 October 2022

f)

Place of the transaction

Euronext Growth Market Dublin

g)

Additional Information

N/A

Enquiries:
HealthBeacon: Laurence Flavin	Investor.Relations@HealthBeacon.com
Goodbody (Euronext Listing Sponsor and Broker): David Kearney	+353 (1) 667 0420
Stephen Kane
Drury (Public Relations):
Cathal Barry	+353 (0) 87 227 9281
Paul Clifford	+353 (0) 87 327 2161

About HealthBeacon plc

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops smart tools for managing medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company has expanded its offering to growth management with the launch of its integrated Smart Scale and oral adherence with the launch of HB Smart Pillstm which integrate with its existing technology. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEBKDBQABDDAKN